1. Introduction
===============

There have been many reports documenting the diversity of secondary metabolites produced by soft corals from the genus *Sinularia*, including sesquiterpenes \[[@B1-marinedrugs-10-01619],[@B2-marinedrugs-10-01619]\], diterpenes \[[@B3-marinedrugs-10-01619],[@B4-marinedrugs-10-01619],[@B5-marinedrugs-10-01619],[@B6-marinedrugs-10-01619],[@B7-marinedrugs-10-01619]\], cembranoids \[[@B8-marinedrugs-10-01619],[@B9-marinedrugs-10-01619],[@B10-marinedrugs-10-01619],[@B11-marinedrugs-10-01619]\], polyhydroxylated steroids \[[@B12-marinedrugs-10-01619]\], glycosides \[[@B13-marinedrugs-10-01619]\], sphingosines \[[@B14-marinedrugs-10-01619]\], farnesyl quinols \[[@B15-marinedrugs-10-01619],[@B16-marinedrugs-10-01619]\], and polyamines \[[@B17-marinedrugs-10-01619]\]. These metabolites have been shown to possess a range of biological activities including antimicrobial \[[@B5-marinedrugs-10-01619]\], antiviral \[[@B4-marinedrugs-10-01619]\], anti-inflammatory \[[@B4-marinedrugs-10-01619],[@B11-marinedrugs-10-01619]\], cytotoxic \[[@B8-marinedrugs-10-01619],[@B9-marinedrugs-10-01619],[@B10-marinedrugs-10-01619],[@B17-marinedrugs-10-01619]\], anticancer \[[@B3-marinedrugs-10-01619],[@B18-marinedrugs-10-01619]\], antifouling \[[@B19-marinedrugs-10-01619]\], antifeedant \[[@B20-marinedrugs-10-01619]\], and allelopathic \[[@B21-marinedrugs-10-01619],[@B22-marinedrugs-10-01619]\] activities. Given this wide-ranging diversity in chemical structure and biological activity, it is not surprising that soft corals, which do not have a hard calcareous skeleton, are relatively well defended against predation \[[@B20-marinedrugs-10-01619]\] and are effective competitors for space on coral reefs \[[@B21-marinedrugs-10-01619]\]. As a result, the *Sinularia* genus remains an attractive target for the discovery of novel bioactive metabolites.

As part of the biodiscovery program at the Australian Institute of Marine Science (AIMS), the ethanol (EtOH) extract of a Great Barrier Reef soft coral *Sinularia* sp., was determined to have significant activity in the NCI 60 cell line COMPARE analysis \[[@B23-marinedrugs-10-01619]\]. Based on this, the sample was selected for recollection, large scale extraction and workup. The methanol (MeOH) extract of the recollected soft coral tissue was subjected to bioassay-guided fractionation, using C18 flash vacuum liquid chromatography and preparative C18 HPLC, to yield the new nitrogenous diterpene (4*R*\*,5*R*\*,9*S*\*,10*R*\*,11*Z*)-4-methoxy-9-((dimethylamino)-methyl)-12,15-epoxy-11(13)-en-decahydronaphthalen-16-ol (**1**), the new lobane, (1*R\**,2*R\**,4*S\**,15*E*)-loba-8,10,13(14),15(16)-tetraen-17,18-diol-17-acetate (**2**), and eight known diterpenes: two cembranes, sarcophytol-B \[[@B24-marinedrugs-10-01619]\] and (1*E*,3*E*,7*E*)-11,12-epoxycembratrien-15-ol \[[@B8-marinedrugs-10-01619]\], and six known lobanes, loba-8,10,13(15)-triene-16,17,18-triol \[[@B25-marinedrugs-10-01619]\], 14,18-epoxyloba-8,10,13(15)-trien-17-ol \[[@B26-marinedrugs-10-01619]\], lobatrientriol \[[@B7-marinedrugs-10-01619]\], lobatrienolide \[[@B7-marinedrugs-10-01619]\], 14,17-epoxyloba-8,10,13(15)-trien-18-ol-18-acetate \[[@B26-marinedrugs-10-01619]\] and (17*R*)-loba-8,10,13(15)-trien-17,18-diol \[[@B27-marinedrugs-10-01619]\]. The structural elucidation and biological activities of **1**, **2** and of the known compounds loba-8,10,13(15)-triene-16,17,18-triol, 14,17-epoxyloba-8,10,13(15)-trien-18-ol-18-acetate, lobatrienolide, (1*E*,3*E*,7*E*)-11,12-epoxycembratrien-15-ol and sarcophytol-B against a panel of human tumour cell lines are also presented.

2. Results and Discussion
=========================

The ^13^C NMR and ESI-FTMS of **1** established its molecular formula to be C~24~H~43~O~3~N, requiring four degrees of unsaturation. The ^1^H and ^13^C NMR spectral data of **1** ([Table 1](#marinedrugs-10-01619-t001){ref-type="table"}) showed the molecule to contain a trisubstituted double-bond (δ~C~ 142.5, s, C-11; 117.8, d, C-13; δ~H~ 5.59, d, 5.2, H-13) as the only multiple bond within the molecule and accounted for one of the degrees of unsaturation. This information, in combination with the molecular formula, showed the molecule to be tricyclic.
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###### 

^1^H and ^13^C NMR data (300 MHz and 75 MHz, CD~3~OD) for (4*R*\*,5*R*\*,9*S*\*,10*R*\*,11*Z*)-4-methoxy-9-((dimethylamino)-methyl)-12,15-epoxy-11(13)-en-decahydronaphthalen-16-ol (**1**).

  No.                         13C δ (m)                1H δ (m, J Hz)             COSY                     gHMBC                      nOe
  --------------------------- ------------------------ -------------------------- ------------------------ -------------------------- -------------------------------
  1                           42.3 (t)                 1.84 (1H, m)               H~b~-1, H~b~-2           C-10, C-5, C-9, C-2, C-3   
  1.24 (1H, m)                H~a~-1, H~a~-2, H~b~-2   C-5, C-19, C-2                                                                 
  2                           28.1 (t)                 1.59 (1H, m )              H~a~-1, H~a~-3           C-4                        
  1.45 (1H, m)                H~a~-1                   C-10, C-1, C-4                                                                 
  3                           36.3 (t)                 1.85 (1H, m)               H~a~-2, H~b~-3           C-5, C-1, C-4, C-20        
  1.60 (1H, m)                H~b~-2, H~a~-3           C-5, C-1, C-4                                                                  
  4                           76.8 (s)                                                                                                
  5                           53.1 (d)                 1.49 (1H, m)               H~2~-6                   C-6, C-19, C-4, C-20       
  6                           26.7 (t)                 1.82 (2H, m)               H-5, H-7                 C-10, C-8                  
  7                           43.1 (d)                 1.86(1H, m)                H~2~-6                   C-5, C-8, C-9              
  8                           25.0 (t)                 1.85 (1H, m)               H~b~-8, H-9                                         
  1.52 (1H, m)                H~a~-8                   C-10, C-7, C-22                                                                
  9                           45.2 (d)                 1.52 (1H, m)               H~a~-22, H~b~-22         C-10, C-7, C-22            
  10                          38.0 (s)                                                                                                
  11                          142.5 (s)                                                                                               
  12                          69.0 (t)                 4.16 (2H, brs)             H-13                     C-7, C-11, C-13, C-15      
  13                          117.8(d)                 5.59 (1H, d, 5.2)          H-12, H~a~-14, H~b~-14   C-7, C-12, C-14, C-15      
  14                          26.3 (t)                 2.12 (1H, m)               H-13, H~b~-14, H-15                                 
  2.00 (1H, m)                H-13, H~a~-14, H-15                                                                                     
  15                          81.9 (d)                 3.25 (1H, m)               H~a~-14, H~b~-14         C-17, C-18                 
  16                          72.7 (s)                                                                                                
  17                          25.2 (q)                 1.17 (3H, s)                                        C-15, C-16, C-18           
  18                          25.6 (q)                 1.17 (3H, s)                                        C-15, C-16, C-17           
  19                          15.2 (q)                 0.89 (3H, s)                                                                   H~b~-1, H~b~-2, H-20, H~2~-22
  20                          18.7 (q)                 1.08 (3H, s)                                        C-5, C-4, C-3              H~b~-1, H~b~-2, H-19
  21                          48.1 (q)                 3.16 (3H, s)                                        C-4                        H-5
  22                          60.5 (t)                 3.25 (1H, dd, 3.2, 11.0)   H-9, H~b~-22             C-10, C-8, C-9             
  2.93 (1H, dd, 11.0, 13.1)   H-9, H~a~-22             C-9                                                                            
  23                          45.2 (q)                 2.90 (3H, s)                                        C-22, C-24                 
  24                          45.2 (q)                 2.90 (3H, s)                                        C-22, C-23                 

From the ^1^H-^1^H COSY spectrum of **1** spin systems from H~b~-1 (δ~H~ 1.24, m) to H~2~-3 (δ~H~ 1.85, m; 1.60, m) via H~a/b~-2 (δ~H~ 1.59, m; 1.45, m) and from H-5 (δ~H~ 1.49, m) to H~2~-22 (δ~H~ 3.25, dd, 3.2, 11.0; 2.93, dd, 11.0, 13.1) via H~2~-6 (δ~H~ 1.82, m), H-7 (δ~H~ 1.86 m), H~2~-8 (δ~H~ 1.85, m; 1.52 m) and H-9 (δ~H~ 1.52, m) could be discerned. This information together with cross-peaks in the HMBC spectrum from H~b~-1 and H-5 to C-19 (δ~C~ 15.2, q), from H-20 (δ~H~ 1.08, s) to C-3, C-4 and C-5, and from H-7 to the olefinic C-11 (δ~C~ 142.5, s), showed the presence of a substituted bicyclic ring system.

The ^1^H-NMR spectrum of **1** displayed singlet resonances of a methoxy (-OCH~3~) at δ~H~ 3.16 and an *N*,*N*-dimethyl substituted tertiary amine (-N(CH~3~)~2~) at δ~H~ 2.90. The HMBC correlation from δ~H~ 3.16 (s) to δ~C~ 76.8 (s, C-4) located the methoxy at C-4 while correlations from both H-23/24 to and δ~C~ 60.5 (C-22) located the tertiary amine at C-22.

Further analysis of the ^1^H-^1^H COSY indicated the presence of a spin system from δ~H~ 5.59 (d, 5.2, H-13) to δ~H~ 3.25 (m, H-15) via δ~H~ 2.12 and 2.00 (m, H~2~-14). HMBC correlations from H-13 to C-7 located the C-11 side chain at C-7 of the bicyclic ring system. Based on HMBC correlations from H~3~-17/H~3~-18 to δ~C~ 72.7 (C-16), the two methyl groups with resonances at δ~H~ 1.17 (H-17/18) were connected to a tertiary carbon bearing an OH, forming a propan-2-ol-2-yl moiety \[[@B28-marinedrugs-10-01619]\]. The data so far accounted for three of the four oxygens, the double-bond, two of the rings, and the nitrogen, leaving one oxygen and one ring unassigned. An ether linkage, forming the third ring, was deduced between C-12 and C-15 based on the HMBC correlation from δ~H~ 4.16 (brs, H-12) to δ~C~ 81.9 (C-15), and was further supported by a C-O-C stretch at 1080 cm^−1^ in the IR spectrum of **1**. Hence the planar structure of **1**, a diterpene, is best described as (4*R*\*,5*R*\*,9*S*\*,10*R*\*,11*Z*)-4-methoxy-9-((dimethylamino)-methyl)-12,15-epoxy-11(13)-en-decahydronaphthalen-16-ol ([Scheme 1](#marinedrugs-10-01619-f002){ref-type="scheme"}).

![Structures of (4*R*\*,5*R*\*,9*S*\*,10*R*\*,11*Z*)-4-methoxy-9-((dimethylamino)-methyl)-12,15-epoxy-11(13)-en-decahydronaphthalen-16-ol (**1**), and (1*R\**,2*R\**,4*S\**,15*E*)-loba-8,10,13(14),15(16)-tetraen-17,18-diol-17-acetate (**2**).](marinedrugs-10-01619-g002){#marinedrugs-10-01619-f002}

The nOe data of **1** showed correlations between H~3~-19 (δ~H~ 0.89, s) and H~b~-1, H~b~-2, H~3~-20 and H~b~-22. These cross peaks revealed the two fused six-membered rings to have a trans-ring junction, CH~3~-19 and CH~3~-20 to be axial and therefore on the same side of **1**, and the side-chain at C-9 to be on the same side as C-19 ([Figure 1](#marinedrugs-10-01619-f001){ref-type="fig"}). Furthermore, nOe correlations were observed between H~3~-21 and H-5 indicating they were on the same side of the molecule as each other but the opposite side of C-19 ([Figure 1](#marinedrugs-10-01619-f001){ref-type="fig"}). The configurations at C-7 and C-15 remain unresolved. Based on the above findings, the relative configurations of chiral carbons C-10, C-5, C-9 and C-4 of **1** were assigned as 4*R*\*, 5*R*\*, 9*S*\* and 10*R*\* ([Scheme 1](#marinedrugs-10-01619-f002){ref-type="scheme"}).

![Diagnositic nOe correlations for partial structure of **1**.](marinedrugs-10-01619-g001){#marinedrugs-10-01619-f001}

The ^13^C NMR and ESI-FTMS of **2** established its molecular formula as C~20~H~34~O~3~, indicating the molecule to have four degrees of unsaturation. The ^1^H and ^13^C NMR spectral data of **2** ([Table 2](#marinedrugs-10-01619-t002){ref-type="table"}) showed it contained a vinyl moiety (δ~C~ 151.6, d, C-8; 110.4, t, C-9; δ~H~ 5.87, dd, 10.8, 17.6 Hz, H-8; δ~H~ 4.93, dd, 1.2, 17.6 Hz, H~a~-9; δ~H~ 4.90, dd, 1.2, 10.8 Hz, H~b~-9), an isopropenyl group (δ~C~ 148.9, s, C-10; 112.7, t, C-11, 25.3, q, C-12; δ~H~ 4.81, brt, 1.5 Hz, H~a~-11; 4.59, brs, H~b~-11; 1.71, brs, H~3~-12) and a tertiary methyl group (δ~C~ 17.1, q, C-7; δ~H~ 1.03, s, H~3~-7), characteristic of the 3-isopropenyl-4-methyl-4-vinylcyclohexane-1-yl moiety found in lobane-type diterpenoids \[[@B7-marinedrugs-10-01619],[@B25-marinedrugs-10-01619],[@B26-marinedrugs-10-01619],[@B27-marinedrugs-10-01619]\]. This partial structure was confirmed by analysis of the COSY, HMQC, and HMBC NMR spectral data of **2**. The relative configuration about C-1 and C-2 in **2** was found to be the same as in elemol and several other lobanes, as established by comparison of the ^1^H and ^13^C NMR data for each molecule at centres C-1, C-2, C-6, C-7, C-8, C-9, C-10, C-11 and C-12 \[[@B25-marinedrugs-10-01619],[@B27-marinedrugs-10-01619]\]. Also evident from this data was an exo-methylene (δ*~C~* 151.9, s, C-13; 114.3, t, C-14; δ~H~ 5.06, s, H~2~-14), an endo-disubstituted double-bond (δ*~C~* 137.4, d,C-15; 124.4, d, C-16; δ~H~ 6.26, d, 16.0, H-15; 5.78, dd, 7.6, 16.0, H-16), a carbonyl group in the form of an acetate (δ~C~ 172.1, s, O-CO-CH~3~; 21.1, q; δ~H~ 2.09, s, O-CO-CH~3~), a CH bearing the acetate (δ~C~ 82.2, d, C-17; δ~H~ 5.14, brd, 7.6, H-17), and a propan-2-ol-2-yl moiety the same as that found in **1**. These assignments were corroborated by the IR data with terminal vinyl C-H stretches at 3079 and 3012 cm^−1^, a carbonyl ester band at 1734 cm^−1^, and an alcohol OH stretch at 3084 cm^−1^. This data accounted for all of the remaining unsaturation within the molecule as well as the previously unaccounted for C~10~H~15~O~3~. From the HMBC data of **2** ([Table 2](#marinedrugs-10-01619-t002){ref-type="table"}), it was evident that C-17 bonded to both C-15 and C-18, as well as the oxygen of the acetyl function. Further, HMBC correlations between H-14 and the carbons C-4, C-13 and C-15, confirmed the side-chain to be attached at C-4 and that the two double-bonds were conjugated, an observation supported by the UV maxima of **2** at 227 nm. With the planar structure of **2** deduced, the double-bond geometry and stereochemistry required resolution. The magnitude of the coupling constant between H-15 and H-16 (*J* = 16.0 Hz), showed Δ^15^ to have *E* geometry. The relative configurations at C-1 and C-2 were confirmed to be the same as in the known lobane loba-8,10,13(15)-triene-16,17,18-triol \[[@B25-marinedrugs-10-01619]\] on the basis of comparable ^13^C NMR chemical shift for the same centres. The relative configurations at C-1, C-2 and C-4 were assigned based on NOESY NMR correlations from H-4 to H-2, H~2~-5, H~a~-6, H-14, H-15, H-16, H~3~-19, H~3~-20 and O-CO-CH~3~, and from H-12 to H-2, H~a~-6, H-7, H-8, H~a~-9, H~2~-11, H~3~-19 and confirmed them to be 1*R\**, 2*R\** and 4*S\**, as shown for **2** \[[@B6-marinedrugs-10-01619],[@B7-marinedrugs-10-01619],[@B25-marinedrugs-10-01619],[@B26-marinedrugs-10-01619],[@B27-marinedrugs-10-01619]\]. The configuration at C-17 remains unresolved. Compound **2** is thus best described as (1*R\**,2*R\**,4*S\**,15*E*)-loba-8,10,13(14),15(16)-tetraen-17,18-diol-17-acetate.
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^1^H and ^13^C NMR data (300 MHz and 75 MHz, CD~3~OD) for (1*R\**,2*R\**,4*S\**,15*E*)-loba-8,10,13(14),15(16)-tetraen-17,18-diol-17-acetate (**2**).

  No.                        ^13^C δ (m)        ^1^H δ (m, *J* Hz)               COSY                  gHMBC                                      nOe
  -------------------------- ------------------ -------------------------------- --------------------- ------------------------------------------ -----------------------------------------------------------------------
  1                          41.0 (s)                                                                                                             
  2                          54.1(d)            2.13 (1H, m)                     H-3                   C-1, C-4, C-7, C-10, C-11, C-12            H-4, H-12
  3                          35.2 (t)           1.66 (2H, m)                     H-2, H-4              C-2, C-4                                   
  4                          41.5 (d)           2.31 (1H, tdd, 3.4, 4.2, 11.7)   H-3, H~a~-5, H~b~-5   C-3, C-13, C-14                            H-2, H~a~-5, H~b~-5, H~a~-6, H-14, H-15, H-16, H-19, H-20, O-CO-CH~3~
  5                          28.8 (t)           1.64 (1H, m)                     H-4, H~b~-5, H~a~-6   C-3                                        H-4
  1.52 (1H, m)               H-4, H~a~-5        C-1, C-4                         H-2, H-4                                                         
  6                          41.2 (t)           1.60 (1H, m)                     H~a~-5, H~b~-6        C-1, C-2, C-4, C-5, C-7                    H-4, H-12
  1.45 (1H, m)               H~a~-6             C-2, C-4, C-5                                                                                     
  7                          17.1 (q)           1.03 (3H, s)                                           C-1, C-2, C-6, C-8                         H-12
  8                          151.6 (d)          5.87 (1H, dd, 10.8, 17.6)        H~a~-9                C-1, C-2, C-6, C-7                         H-12
  9                          110.4 (t)          4.93 (1H, dd, 1.2. 17.6)         H-8, H~b~-9           C-1, C-2, C-8                              H-12, H-17
  4.90 (1H, dd, 1.2, 10.8)   H-8, H~b~-9        C-1, C-2, C-8                    H-17                                                             
  10                         148.9 (s)                                                                                                            
  11                         112.7 (t)          4.81 (1H, brt, 1.5)              H~b~-11, H~3~-12      C-1, C-2, C-10, C-12                       H-12
  4.59 (1H, brs)             H~a~-11, H~3~-12   C-1, C-2, C-10, C-12             H-12                                                             
  12                         25.3 (q)           1.71 (3H, brs)                   H~a~-11, H~b~-11      C-1, C-2, C-10, C-11                       H-2, H~a~-6, H-7, H-8, H~a~-9, H~a~-11, H~b~-11, H-19
  13                         151.9 (s)                                                                                                            
  14                         114.3 (t)          5.06 (2H, s)                                           C-4, C-13, C-15, C-16                      H-4
  15                         137.4(d)           6.26 (1H, d, 16.0)               H-16                  C-4, C-13, C-14, C-16, C-17                H-4, H-17
  16                         124.4 (d)          5.78 (1H, dd, 7.6, 16.0)         H-15, H-17            C-13,C-14, C-17, C-18                      H-4, H-17
  17                         82.2 (d)           5.14 (1H, brd, 7.6)              H-16                  C-15, C-16, C-18, C-19, C-20, O-CO-CH~3~   H~a~-9, H~b~-9, H-15, H-16, H-19, H-20, O-CO-CH~3~
  18                         72.7 (s)                                                                                                             
  19                         25.6 (q)           1.17 (3H, s)                                           C-17, C-18, C-20                           H-4, H-12, H-17, O-CO-CH~3~
  20                         26.2 (q)           1.18 (3H, s)                                           C-17, C-18, C-19                           H-4, H-17, O-CO-CH~3~
  O-CO-CH~3~                 172.1 (s)                                                                                                            
  O-CO-CH~3~                 21.1 (q)           2.09 (3H, s)                                           OAc                                        H-4, H-7, H-17, H-19, H-20

Complete 1D and 2D NMR data for the known cembranes: sarcophytol-B and (1*E*,3*E*,7*E*)-11,12-epoxycembratrien-15-ol, and the six known lobanes: loba-8,10,13(15)-triene-16,17,18-triol, 14,18-epoxyloba-8,10,13(15)-trien-17-ol, lobatrientriol, lobatrienolide, 14,17-epoxyloba-8,10,13(15)-trien-18-ol-18-acetate and (17*R*)-loba-8,10,13(15)-trien-17,18-diol, are provided for the first time ([Supplementary Information](#marinedrugs-10-01619-s001){ref-type="supplementary-material"}). Raju *et al.* reported that loba-8,10,13(15)-triene-16,17,18-triol was the product of long-term, cold storage of the natural product 17,18-epoxyloba-8,10,13(15)-trien-16-ol in CDC1~3~ \[[@B25-marinedrugs-10-01619]\]. Closer inspection of the FTMS and ^13^C NMR of the fresh extract in CD~3~OD showed the presence of only the triol in our study.

The cytotoxic activities of compounds **1** and **2**, and of the known compounds loba-8,10,13(15)-triene-16,17,18-triol, 14,17-epoxyloba-8,10,13(15)-trien-18-ol-18-acetate, lobatrienolide, (1*E*,3*E*,7*E*)-11,12-epoxycembratrien-15-ol and sarcophytol-B towards a panel of human tumour cell lines are given in [Table 3](#marinedrugs-10-01619-t003){ref-type="table"}. With the exception of **1** (GI~50~s all over 70 μM), all compounds showed good activity with GI~50~s in the range 6.8--18.5 µM. From these data there appears to be no obvious SAR. The four lobanes (including **2**) and the two cembranes all had approximately the same overall activities against the human tumour cell lines SF-268, MCF-7 and H460, with no selectivity.
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Cytotoxicity data \[GI~50~ (µM)\] for compounds **1**, **2** and the known compounds loba-8,10,13(15)-triene-16,17,18-triol, 14,17-epoxyloba-8,10,13(15)-trien-18-ol-18-acetate, lobatrienolide, (1*E*,3*E*,7*E*)-11,12-epoxycembratrien-15-ol and sarcophytol-B against the human tumour cell lines SF-268, MCF-7 and H460.

  Compound                                             SF-268 ^a^   MCF-7 ^b^   H460 ^c^
  ---------------------------------------------------- ------------ ----------- ----------
  **1**                                                175          70          125
  **2**                                                15           8.8         11.5
  Loba-8,10,13(15)-triene-16,17,18-triol               18.5         17          13
  Lobatrientriol                                       NT           NT          NT
  14,17-Epoxyloba-8,10,13(15)-trien-18-ol-18-acetate   14           16          18.5
  Lobatrienolide                                       7.4          17          18
  14,18-Epoxyloba-8,10,13(15)-trien-17-ol              NT           NT          NT
  (17*R*)-Loba-8,10,13(15)-trien-17,18-diol            NT           NT          NT
  (1*E*,3*E*,7*E*)-11,12-Epoxycembratrien-15-ol        6.8          12          18.5
  Sarcophytol-B                                        16           12.5        15

^a^ SF-268 Central nervous system-glioblastoma cells; ^b^ MCF-7 Breast-pleural effusion adenocarcinoma cells; ^c^ H460 Lung-large cell carcinoma cells; NT = Not tested.

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

General experimental procedures are as described previously \[[@B29-marinedrugs-10-01619]\].

3.2. Animal Material
--------------------

The soft coral *Sinularia* sp., (Order Alcyonacea, Family Alcyoniidae) was collected from the eastern edge of the lagoon at Bowden Reef (19°2.1′S, 147°56.0′E) in the Central Great Barrier Reef, Queensland, Australia, at a depth of 9 m, in June 2005. Collection of this material was conducted under the GBRMPA Permit no. G05/11866.1 and kept frozen (−20 °C) until work-up. A voucher specimen (AIMS 27026) has been lodged with the AIMS Bioresources Library.

3.3. Bioassay
-------------

Cellular bioassays were undertaken as described previously \[[@B29-marinedrugs-10-01619]\].

3.4. Extraction and Isolation
-----------------------------

Freeze dried animal material (29.6 g) was extracted with MeOH (3 × 400 mL) and a butanol:CH~2~Cl~2~:H~2~O (150:50:100 mL) partition performed. The aqueous phase was further partitioned with BuOH:CH~2~Cl~2~ (150:50 mL) and the organic phase added to the first organic fraction. The organic fraction (16.8 g) was then subjected to reversed phase C18 flash vacuum chromatography (RP-C18, 25%, 50%, 75%, 100% MeOH in H~2~O and 1:1 MeOH:CH~2~Cl~2~). Activity was observed for the first four fractions. A portion of the 25% MeOH fraction (3.44 g of 10.27 g) was pre-absorbed onto C18, packed into a cartridge, and further separated by preparative C18 HPLC (52 mL/min, isocratic elution at 15% CH~3~CN:H~2~O for 3 min followed by gradient elution from 15% CH~3~CN:H~2~O to 100% CH~3~CN:H~2~O over 50 min and an isocratic elution at 100% CH~3~CN for 30 min through a 250 × 41.1 mm Varian Dynamax Microsorb 60-8 C18 column), fractions were collected every 30 s (*n* = 176) to yield (in order of elution) (4*R*\*,5*R*\*,9*S*\*,10*R*\*,11*Z*)-4-methoxy-9-((dimethylamino)-methyl)-12,15-epoxy-11(13)-en-decahydronaphthalen-16-ol (**1**, fr 19 and 20 combined, 18.3 mg, 0.06% dry wt of extract), lobatrientriol \[[@B7-marinedrugs-10-01619]\] (fr 71, 24.6 mg, 0.08% dry wt of extract), loba-8,10,13(15)-triene-16,17,18-triol (fr 81, 21.1 mg, 0.07% dry wt of extract), 14,17-epoxyloba-8,10,13(15)-trien-18-ol-18-acetate \[[@B26-marinedrugs-10-01619]\] (fr, 83 and 84 combined, 72.8 mg, 0.07% dry wt of extract), lobatrienolide \[[@B7-marinedrugs-10-01619]\] (fr 87, 24.9 mg, 0.08% dry wt of extract), (1*E*,3*E*,7*E*)-11,12-epoxycembratrien-15-ol \[[@B8-marinedrugs-10-01619]\] (fr 89, 30.9 mg, 0.10% dry wt of extract) and 14,18-epoxyloba-8,10,13(15)-trien-17-ol \[[@B26-marinedrugs-10-01619]\] (fr 109, 123.7 mg, 0.42% dry wt of extract). Fractions 100 to 102 were combined (108.4 mg) and further purified by C18 analytical HPLC (1 mL/min, gradient elution from 5% CH~3~CN:H~2~O to 100% CH~3~CN over 18 min, followed by 6 min with 100% CH~3~CN through 250 × 4.6 mm, 5μ Phenomenex Luna (2) C18 column and fractions collected every 30 s) to yield the known compounds (17*R*)-loba-8,10,13(15)-triene-17,18-diol \[[@B27-marinedrugs-10-01619]\] (fr 34, 6.2 mg, 0.02% dry wt of extract) and sarcophytol-B \[[@B24-marinedrugs-10-01619]\] (fr 36, 18.3 mg, 0.06% dry wt of extract) and the new compound (1*R\**,2*R\**,4*S\**,15*E*)-loba-8,10,13(14),15(16)-tetraen-17,18-diol-17-acetate (**2**, fr 33, 2.3 mg, 0.008% dry wt of extract). The known compounds had identical physical and spectroscopic properties to those previously published \[[@B7-marinedrugs-10-01619],[@B8-marinedrugs-10-01619],[@B24-marinedrugs-10-01619],[@B26-marinedrugs-10-01619],[@B27-marinedrugs-10-01619]\].

### 3.4.1. (4*R*\*,5*R*\*,9*S*\*,10*R*\*,11*Z*)-4-Methoxy-9-((dimethylamino)-methyl)-12,15-epoxy-11(13)-en-decahydronaphthalen-16-ol (**1**)

Pale yellow oil. \[α\]^24^~D~ +72° (CH~3~OH; *c* 0.67); UV (PDA) λ~max~ nm: 195, 208; IR ν~max~ cm^−1^: 3388, 2969, 2935, 1645, 1468, 1384, 1161, 1080; ^1^H (300 MHz, CD~3~OD) and ^13^C (75 MHz, CD~3~OD) NMR data [Table 1](#marinedrugs-10-01619-t001){ref-type="table"}; ESI-FTMS *m/z* \[M + H\]^+^ 394.3316 (calcd for C~24~H~44~O~3~N 394.3303), \[M + Na\]^+^ 416.3128 (calcd for C~24~H~43~O~3~NNa 416.3135).

### 3.4.2. (1*R*\*,2*R*\*,4*S*\*,15*E*)-Loba-8,10,13(14),15(16)-tetraen-17,18-diol-17-acetate (**2**)

Colourless oil. \[α\]^24^~D~ −9.5° (CH~3~OH; *c* 0.23); UV (PDA) λ~max~ nm: 203, 227; IR ν~max~ cm^−1^: 3408, 2963, 2926, 1734, 1635, 1455, 1372, 1234, 1024, 904; ^1^H (300 MHz, CD~3~OD) and ^13^C (75 MHz, CD~3~OD) NMR data [Table 2](#marinedrugs-10-01619-t002){ref-type="table"}; ESI-FTMS *m/z* \[M + Na\]^+^ 369.2396 (calcd for C~22~H~34~O~3~Na 369.2400).

### 3.4.3. Loba-8,10,13(15)-triene-16,17,18-triol

Colourless oil. ^1^H-NMR and ^13^C-NMR spectral data were consistent with published values \[[@B25-marinedrugs-10-01619]\]; ESI-FTMS *m/z* \[M + Na\]^+^ 345.2398 (calcd for C~20~H~34~O~3~Na 345.2400).

### 3.4.4. Lobatrientriol

Colourless oil. ^1^H-NMR and ^13^C-NMR spectral data were consistent with published values \[[@B7-marinedrugs-10-01619]\].

### 3.4.5. 14,17-Epoxyloba-8,10,13(15)-trien-18-ol-18-acetate

Colourless oil. ^1^H-NMR and ^13^C-NMR spectral data were consistent with published values \[[@B26-marinedrugs-10-01619]\].

### 3.4.6. Lobatrienolide

Colourless oil. ^1^H-NMR and ^13^C-NMR spectral data were consistent with published values \[[@B7-marinedrugs-10-01619]\].

### 3.4.7. (1*E*,3*E*,7*E*)-11,12-Epoxycembratrien-15-ol

Colourless oil. ^1^H-NMR and ^13^C-NMR spectral data were consistent with published values \[[@B8-marinedrugs-10-01619]\].

### 3.4.8. 14,18-Epoxyloba-8,10,13(15)-trien-17-ol

Colourless oil. ^1^H-NMR and ^13^C-NMR spectral data were consistent with published values \[[@B26-marinedrugs-10-01619]\].

### 3.4.9. (17*R*)-Loba-8,10,13(15)-trien-17,18-diol

Colourless oil. ^1^H-NMR and ^13^C-NMR spectral data were consistent with published values \[[@B27-marinedrugs-10-01619]\].

### 3.4.10. Sarcophytol-B

Colourless oil. ^1^H-NMR and ^13^C-NMR spectral data were consistent with published values \[[@B24-marinedrugs-10-01619]\].

4. Conclusion
=============

Two new compounds, the somewhat unprecedented nitrogen containing (4*R*\*,5*R*\*,9*S*\*,10*R*\*,11*Z*)-4-methoxy-9-((dimethylamino)-methyl)-12,15-epoxy-11(13)-en-decahydronaphthalen-16-ol (**1**) and the lobane (1*R\**,2*R\**,4*S\**,15*E*)-loba-8,10,13(14),15(16)-tetraen-17,18-diol-17-acetate (**2**), together with the eight known compounds sarcophytol-B \[[@B24-marinedrugs-10-01619]\], (1*E*,3*E*,7*E*)-11,12-epoxycembratrien-15-ol \[[@B8-marinedrugs-10-01619]\], loba-8,10,13(15)-triene-16,17,18-triol \[[@B25-marinedrugs-10-01619]\], 14,18-epoxyloba-8,10,13(15)-trien-17-ol \[[@B26-marinedrugs-10-01619]\], lobatrientriol \[[@B7-marinedrugs-10-01619]\], lobatrienolide \[[@B7-marinedrugs-10-01619]\], 14,17-epoxyloba-8,10,13(15)-trien-18-ol-18-acetate \[[@B26-marinedrugs-10-01619]\] and (17*R*)-loba-8,10,13(15)-trien-17,18-diol \[[@B27-marinedrugs-10-01619]\], were isolated from the Australian soft coral *Sinularia* sp. Although there are many publications detailing the isolation of lobanes \[[@B6-marinedrugs-10-01619],[@B7-marinedrugs-10-01619]\] and cembranes \[[@B8-marinedrugs-10-01619],[@B9-marinedrugs-10-01619],[@B11-marinedrugs-10-01619]\] from soft corals of the genus *Sinularia*, this report shows that new investigations are still yielding further new and somewhat unprecedented derivatives, and that continued investigations of this genus are warranted. The biological and pharmacological properties associated with soft coral chemistry, in particular terpenoids, have been shown to be highly promising \[[@B30-marinedrugs-10-01619]\], leading to the need for more extensive structure-activity relationship studies and further evaluation of their mechanism of action.

Collection of this soft coral was made possible through the access and benefit sharing arrangements between AIMS and the Australian Commonwealth Government. The authors are grateful to those AIMS staff, both past and present, involved in the collection. We thank A.-M. Babey, School of Veterinary and Biomedical Sciences, James Cook University for initial cytotoxicity screening data and for the SF-268 cell line and C. Hooi, R. Anderson and C. Cullinane, of the Peter MacCallum Cancer Centre, Melbourne, Australia, for the MCF-7 and H460 cell lines.
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